[ 177 Lu]Lu-PSMA-617 (Pluvicto), a new radioligand therapy that targets prostate-specific membrane antigen (PSMA), has been approved to treat metastatic castration-resistant prostate cancer (
Radioligand Therapy market to grow at a significant CAGR of 4.67% during 2021-2031. Radioligand Therapy market report by BIS Research provides deep market insight, industry analysis, trends & forecast
Dataset 1. PPI data. The percent PPI data is provided for each prepulse decibel level tested. This raw behavioral data reflects the percentage of inhibition in prepulse-pulse trials compared with puls
